Correction to: Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial

Junichi Takada; Rajani Dinavahi; Akimitsu Miyauchi; Etsuro Hamaya; Toshiyasu Hirama; Cesar Libanati; Yoichi Nakamura; Cassandra E Milmont; Andreas Grauer

doi:10.1007/s00774-020-01099-w

Correction to: Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial

J Bone Miner Metab. 2020 Jul;38(4):605. doi: 10.1007/s00774-020-01099-w.

Authors

Junichi Takada¹, Rajani Dinavahi², Akimitsu Miyauchi³, Etsuro Hamaya⁴, Toshiyasu Hirama⁴, Cesar Libanati⁵, Yoichi Nakamura⁴, Cassandra E Milmont², Andreas Grauer²

Affiliations

¹ Kitago Orthopedic Clinic, Hokkaido, Japan. [email protected].
² Amgen Inc., Thousand Oaks, CA, USA.
³ Miyauchi Medical Center, Osaka, Japan.
⁴ Amgen Astellas BioPharma K.K., Tokyo, Japan.
⁵ UCB Pharma, Brussels, Belgium.

PMID: 32198616
DOI: 10.1007/s00774-020-01099-w

Abstract

In the original publication of the article, the last row of Table 1 was published incorrectly as "Serum P1NP (μmol/L), median (IQR)^b : Romosozumab, 25 (18, 34); Teriparatide, 25 (20, 33)". The correct row should be read as "Serum P1NP (μg/L), median (IQR)^b : Romosozumab, 25 (18, 34); Teriparatide, 25 (20, 33)".

Publication types

Published Erratum